BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

725 related articles for article (PubMed ID: 19337180)

  • 1. Treatment of iron overload in thalassemia.
    Cianciulli P
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():208-13. PubMed ID: 19337180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias.
    Ault P; Jones K
    Clin J Oncol Nurs; 2009 Oct; 13(5):511-7. PubMed ID: 19793708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD; Taher A
    Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
    Greenberg PL
    J Natl Compr Canc Netw; 2006 Jan; 4(1):91-6. PubMed ID: 16403408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron mobilization using chelation and phlebotomy.
    Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ
    J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
    Marsella M; Borgna-Pignatti C
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral iron chelators.
    Kwiatkowski JL
    Hematol Oncol Clin North Am; 2010 Feb; 24(1):229-48. PubMed ID: 20113905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP; Yang YS; Yao CY; Peng CT
    Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeuetic management of patients with thalassemia major].
    Thuret I
    Bull Soc Pathol Exot; 2001 May; 94(2):95-7. PubMed ID: 11475036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron chelation therapy for transfusional iron overload: a swift evolution.
    Musallam KM; Taher AT
    Hemoglobin; 2011; 35(5-6):565-73. PubMed ID: 21910602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
    Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
    Farmaki K; Tzoumari I; Pappa C
    Blood Cells Mol Dis; 2011 Jun; 47(1):33-40. PubMed ID: 21531154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron loading and its clinical implications.
    Hershko C
    Am J Hematol; 2007 Dec; 82(12 Suppl):1147-8. PubMed ID: 17963253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing iron chelation strategies in beta-thalassaemia major.
    Porter JB
    Blood Rev; 2009 Dec; 23 Suppl 1():S3-7. PubMed ID: 20116637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR; De Sanctis V; Gilli G
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proceedings of the 17th International Conference on Chelation: application of effective chelation therapies in iron loading and non iron loading conditions, and the gap in the prevention and treatment policies on thalassemia between developed and developing countries.
    Kontoghiorghes GJ
    Hemoglobin; 2009; 33(5):283-6. PubMed ID: 19814673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
    Gattermann N
    Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.